Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on Friday, pricing the lowest dose of 0 ...

Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week as it targets a fast-growing ...

Indian health-tech startup Healthify is in talks to partner with more weight-loss drugmakers to offer health, nutrition and ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

The launch comes amid the company’s legal battle with Indian drugmakers, including Dr Reddy’s Laboratories and Sun Pharma, ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus Research to Hold from Buy on December 8th, The ...

Danish pharmaceutical company Novo Nordisk today launched its blockbuster type 2 diabetes treatment injection Ozempic in ...

Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 (approx ₹ 2,200) per week, as it seeks ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Danish drugmaker Novo ‍Nordisk launched its blockbuster diabetes drug Ozempic in ‌India on ‌Friday. Ozempic, a once-weekly ...